Functionalized mesoporous silica nanoparticles in anticancer therapeutics.


Journal

Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218

Informations de publication

Date de publication:
02 2021
Historique:
received: 08 08 2019
revised: 15 08 2019
accepted: 20 08 2019
pubmed: 24 8 2019
medline: 4 3 2022
entrez: 24 8 2019
Statut: ppublish

Résumé

The application of nanomedicines in tumor targeting and attaining meaningful therapeutic benefits for the treatment of cancers has been going on for almost two decades. Beyond the lipidic and polymeric nanomedicines-based passive and active targeting, the quest for inventing the new generation of carriers has no end. This has lead to the evolution of some of the unique carrier systems with supramolecular assembly structures. Mesoporous nanoparticulate systems (MSNPs) are the recently explored substances with favorable potential for drug delivery and drug targeting applications especially in cancer chemotherapeutics. Notwithstanding their physical properties that makes them a suitable carrier for cancer treatment, but their outstanding ability towards chemical functionalization helps in delivering the imaging agents for diagnostic applications. MSNPs can improve the dissolution rate and systemic availability of the poorly water soluble drugs due to their mesoporous structures. Besides, guest molecules including targeting ligands, biomimetic agents, fluorescent dyes, and biocompatible polymers can be efficiently encapsulated in their tunable porous structure for targeting purpose. Some special features of the MSNPs which make them one of the highly effective nanocarrier systems include their ability to encapsulate non-crystalline drugs in their mesopores, high dispersion ability as a function of large surface area and wetting properties. For anticancer drug delivery, MSNPs are worthful to provide excellent drug loading capacity and endocytotic behavior. Moreover, the external surface of MSNPs can be precisely modified for tumor-recognition and developing sensitivity of the antitumor agents towards the cancer cells. Owing to the innumerable applications of MSNPs till now in cancer treatment, the present article particularly focuses to provide an overview account with complete details on the topic to make the readers abreast with details on physiochemical and material properties of MSNPs, their applications and current innovations for the purpose.

Identifiants

pubmed: 31442571
pii: S1044-579X(19)30104-X
doi: 10.1016/j.semcancer.2019.08.022
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Silicon Dioxide 7631-86-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

365-375

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Abul Barkat (A)

Department of Pharmaceutics, School of Medical & Allied Sciences, KR Mangalam University, Gurgaon, Sohna, Haryana, India.

Sarwar Beg (S)

Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard (Hamdard University), New Delhi, India. Electronic address: sarwar.beg@jamiahamdard.ac.in.

Sunil K Panda (SK)

Research Director, Menovo Pharmaceuticals Research Lab, Ningbo, People's Republic of China.

Khalid S Alharbi (K)

Department of Pharmacology, College of Pharmacy, Jouf University, Sakakah, Kingdom of Saudi Arabia.

Mahfoozur Rahman (M)

Department of Pharmaceutical Sciences, SIHAS, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, UP, India. Electronic address: mahfoozur.rahman@shiats.edu.in.

Farhan J Ahmed (FJ)

Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard (Hamdard University), New Delhi, India. Electronic address: fjahmad@jamiahamdard.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH